JARID2-AS1

Across TCGA pan-cancer cohorts, JARID2-AS1 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated JARID2-AS1 data layer.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher JARID2-AS1 RNA is associated with better overall survival. In most high-consensus cancer types, elevated JARID2-AS1 expression acts as an unfavorable survival marker, although some lineages such as READ and UVM show a favorable association.

READ, SKCM, and UVM are the cancer types where JARID2-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	III,IV	0.724	0.289	<.001	54	view →
SKCM	OS	Quartile	III,IV	0.563	0.797	.001	41	view →
UVM	DFS	Median	All	0.743	0.383	.002	37	view →
HNSC	OS	Tertile	II,III,IV	0.825	0.616	.004	34	view →
ACC	DFS	Quartile	All	0.281	0.774	.009	30	view →
LUAD	OS	Quartile	III,IV	0.904	0.538	.003	21	view →
CHOL	OS	Median	All	0.960	0.549	.002	20	view →
LIHC	OS	Median	III,IV	0.554	0.204	.009	16	view →
PAAD	OS	Tertile	All	0.530	0.280	.018	15	view →
SARC	DFS	Quartile	All	0.194	0.491	.001	14	view →
MESO	OS	Median	All	0.700	0.319	.021	10	view →
THCA	DFS	Median	III,IV	0.863	0.618	.015	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

JARID2-AS1–READ (OS)

Open the READ breakdown →